1. Clinical Overview
Oxybutynin is a competitive muscarinic acetylcholine receptor antagonist used primarily for the treatment of overactive bladder (OAB) syndrome. It acts as an antispasmodic on smooth muscle, reducing bladder contractility and increasing bladder capacity. The 5mg strength is a standard immediate-release oral tablet formulation widely used in the Indian clinical setting.
| Onset | Duration | Bioavailability |
|---|---|---|
| 30 to 60 minutes after oral administration. | Approximately 6 to 10 hours for the immediate-release formulation. | Approximately 6% (high first-pass metabolism). |
2. Mechanism of Action
Oxybutynin competitively antagonizes the binding of acetylcholine to muscarinic receptors (M1, M2, M3) on detrusor smooth muscle and other effector sites. In the bladder, this inhibition reduces involuntary detrusor muscle contractions, increases bladder capacity, and delays the initial desire to void.
3. Indications & Uses
- Overactive Bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency.
- Neurogenic bladder instability (e.g., due to spinal cord injury, multiple sclerosis).
4. Dosage & Administration
Adult Dosage: Initial dose: 5 mg orally two to three times daily. Maximum: 5 mg four times daily (20 mg/day). Dose titration should be based on response and tolerability.
Administration: Tablet can be taken with or without food. Swallow whole with a glass of water. Taking with food may minimize GI upset. Maintain adequate fluid intake unless contraindicated.
5. Side Effects
Common side effects may include:
- Dry mouth (up to 70%)
- Constipation
- Blurred vision/dry eyes
- Drowsiness/dizziness
- Headache
- Nausea
- Dyspepsia
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Other Anticholinergics (e.g., Atropine, Dicyclomine, TCAs, Antipsychotics) | Additive anticholinergic effects (dry mouth, constipation, urinary retention, confusion, tachycardia). | Major |
| CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin, Ritonavir) | Increased plasma levels of oxybutynin, leading to enhanced effects and toxicity. | Major |
| CYP3A4 Inducers (e.g., Rifampicin, Carbamazepine, Phenytoin) | Decreased plasma levels of oxybutynin, potentially reducing efficacy. | Moderate |
| Opioid Analgesics | Increased risk of severe constipation and urinary retention. | Moderate |
| Potassium Chloride (wax-matrix tablets) | Increased risk of GI mucosal lesions due to reduced GI motility. | Moderate |
| Metoclopramide | Oxybutynin may antagonize the prokinetic effect of metoclopramide. | Moderate |
| Alcohol, CNS Depressants (Benzodiazepines, Opioids) | Additive sedative effects, impaired alertness. | Moderate |
7. Patient Counselling
- DO take the medication exactly as prescribed, with or without food.
- DO maintain adequate fluid intake unless advised otherwise.
- DO inform your doctor about all other medications you are taking.
- DO use sugar-free gum or candies to relieve dry mouth.
- DO get regular eye check-ups if on long-term therapy.
- DONT stop the medication abruptly without consulting your doctor.
- DONT take a double dose to make up for a missed one.
- DONT drive or operate heavy machinery if you feel drowsy or dizzy.
- DONT expose yourself to excessive heat (sauna, hot weather exercise) as it may cause heatstroke due to decreased sweating.
8. Toxicology & Storage
Overdose: Symptoms are extensions of its pharmacologic effects: severe anticholinergic crisis including CNS disturbances (restlessness, psychosis, hallucinations, drowsiness progressing to coma), cardiovascular effects (tachycardia, hypotension/hypertension, circulatory failure), hyperthermia, flushed/dry skin, dilated pupils, urinary retention, ileus, respiratory depression.
Storage: Store at room temperature (15-30°C), protected from light and moisture. Keep out of reach of children. Do not use after the expiry date printed on the pack.